MiKasome liposomal amikacin data

NXTR (Boulder, Colo.) announced that pilot Phase II data in five patients showed resolution of drug-resistant Mycobacterium tuberculosis infections. Another patient also has been successfully treated after failure with four other antibiotics.

The agent does not produce the typical side effects of kidney and hearing damage when packaged in the liposomal formulation, as demonstrated in Phase I testing. Phase II trials will begin soon, and the agent will also be targeted at drug-resistant gram-negative sepsis. ...